InVivo Therapeutics has appointed Sean Moran to its management team as chief financial officer with responsibility to play a leadership role to drive the development and commercialisation of company's biopolymer scaffolding device for the treatment of spinal cord injury.

Moran brings to InVivo more than 26 years of experience in financial management and 16 years as a CFO for public and private companies. He has a deep background in life sciences and served in senior financial roles for medical device, biotech and drug development companies.

InVivo Therapeutics CEO Frank Reynolds said that the company has recruited world renowned scientists into its team and now the addition of Sean Moran to represents the beginning of building out of the business side of InVivo’s management team.

“In just a short time with InVivo, Sean has already shaped our financial strategies and we look forward to his continued contributions,” Reynolds said.

Moran said that he was thrilled to have joined InVivo and the company’s technology has tremendous potential to help treat patients with devastating spinal cord injuries. He also said that InVivo’s product is moving into human clinical trials and the company is poised for explosive growth.